# A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects

> **NCT01803412** · PHASE3 · TERMINATED · sponsor: **BioMarin Pharmaceutical** · enrollment: 53 (actual)

## Conditions studied

- Muscular Dystrophies

## Interventions

- **DRUG:** Drisapersen
- **DRUG:** Drisapersen
- **DRUG:** Drisapersen

## Key facts

- **NCT ID:** NCT01803412
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05-01
- **Primary completion:** 2016-06-01
- **Final completion:** 2016-10-01
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2018-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803412, "A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01803412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*